Inovio Pharmaceuticals Faces Legal Scrutiny Over Alleged Misleading Statements and Manufacturing Issues

### Legal Challenges Loom for Inovio Pharmaceuticals Amid Allegations of Misleading Statements

Inovio Pharmaceuticals, Inc. faces growing legal scrutiny as several law firms announce class action lawsuits stemming from allegations that the company engaged in misleading practices regarding its operations. Specifically, these suits target statements made by Inovio’s executives between October 10, 2023, and December 26, 2025. Shareholders are encouraged to pursue lead plaintiff status in these lawsuits due to claims of deficiencies in the manufacturing of Inovio's CELLECTRA device and the potential inability to submit their lead product candidate, INO-3107, for FDA approval by the anticipated deadline of mid-2024. The allegations assert that the company lacked sufficient data to substantiate INO-3107's eligibility for expedited regulatory reviews, resulting in misleading projections of the product's commercial and regulatory viability.

The implications of these lawsuits highlight concerns surrounding Inovio's transparency and communication practices. According to the complaints, the company's public disclosures are described as materially false and misleading throughout the relevant period. This lack of transparency raises critical questions about the reliability of the information disseminated to investors and stakeholders. The ramifications of these disclosures may extend beyond financial losses, potentially affecting the company's reputation and credibility within the highly regulated biotechnology industry. As Inovio navigates these legal waters, it must address not only the immediate concerns from investors but also the long-term implications for its business strategy and product pipeline.

Investors who have suffered losses related to Inovio are encouraged to explore their legal options in light of these developments. Law firms, such as The Gross Law Firm and Levi & Korsinsky, LLP, are actively seeking participants for the class action, emphasizing that affected individuals can join without incurring costs. With a lead plaintiff deadline set for April 7, 2026, shareholders are urged to register to monitor the lawsuit's progress and protect their rights. These legal developments underscore the critical importance of corporate accountability and transparency, especially within an industry where consumer safety and regulatory compliance are paramount.

In related developments, the ongoing legal proceedings not only pose challenges for Inovio but could also affect investor sentiment towards the biotechnology sector as a whole. As concerns mount regarding compliance and ethical business practices in the industry, these lawsuits may serve as a cautionary tale for other companies. Stakeholders and investors are advised to stay informed about the potential outcomes of these cases and to consider the broader implications for future collaborations and innovations in biotechnology.